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ABSTR ACT
Recently, the US Food and Drug Administration has given a landmark
approval to the very first digital pill with a sensor embedded in the inside.
These are complex systems that include a drug and an electronic tracker that
is activated when the patient takes the pill. Accordingly, they might be an
excellent tool formonitoring and potentially improving patients’ adherence
to prescriptions. This would serve well to avoid unnecessary healthcare
costs and reduce the anxiety of patients and their relatives. However, digital
pillsmight alsodiminishpatient autonomy, reduceprivacy, or promote inad-
equate use of pharmaceutical resources. This article is aimed at contributing
to adequate use of this new tool by showing the main ethical and social
issues they involve and proposing measures meant to address them. Finally,
we conclude by defending the idea that these new systems should be seen
as means of complementing traditional strategies to promote adherence to
treatment, and not as substitutes.
K E Y W O R D S: Digital health, digital pills, adherence, ingestible sensor, data
protection and privacy, patient autonomy
INTRODUCTION: A GAME-CHANGER TECHNOLOGY IS BORN
On November 13, 2017, a pharmaceutical company Otsuka Pharmaceutical Co., Ltd
(Otsuka), based in Maryland, USA, and a Silicon Valley company, Proteus Digital
Health (Proteus), announced that the US Food and Drug Administration (FDA) had
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with a sensor). This is a drug–device combination product comprised of Otsuka’s
oral aripiprazole tablets embedded with an ingestible event marker (IEM) sensor.1
Aripiprazole is an antipsychotic used to treat adults with schizophrenia, bipolar I
disorder, and major depressive disorder. The drug is part of a more complex product,
i.e. the AbilifyMyCite® System,which comprises theAbilifyMyCite® and the following
components: a wearable sensor developed by Proteus, i.e. the MyCite® Patch; a smart-
phone application (app) called MyCite® app, which can display information about the
patient on a compatible smartphone, and web-based portals for healthcare providers
and caregivers that display a summary of aripiprazole ingestion over time.2
The Abilify MyCite® System offers healthcare providers an astonishing outcome: it
records real-time medication ingestion by patients and collects data on activity level
as well as self-reported rest and mood. The processing is easily described: after the
daily antipsychotic pill is swallowed, a digital sensor the size of a grain of sand (made of
copper, magnesium, and silicon, which Proteus states are all found in food) functions
like a battery by releasing an electric signal to the patchwhen it has reached the stomach
acid. Thus, the adhesive patch on the patient’s torso collects information on the date
and time the pill was taken, blood pressure, temperature, and level of activity. Then,
the patch sends a signal to an app on the patient’s smartphone. At this stage, patients
can add self-reported mental health data about how they are feeling. The app uploads
the data to a secure website on a cloud-based system for viewing by doctors.3 As a
final result, all information gathered by the system can be communicated to patients
and healthcare providers through the electronic devices incorporatedwith the product.
In this manner, it is possible to obtain an objective summary of drug ingestion over
time.4 It is good to highlight that patients can decide who has access to their data at any
moment among other authorized parties, such asOtsuka and its vendors, their selected
healthcare providers, their family and friends, their pharmacy, or their health plan.5
At present, there are good reasons to believe that Abilify MyCite® will soon be
followed by other digital pills. Based on the information gathered, the industry is
producing apps for substance abuse treatment, diabetes management, and heart and
blood pressure monitoring at a rapid clip. At the same time, studies are underway
for digital pills for addressing other mental health pathologies, cancer, cardiovascular
conditions, and infectious diseases, such as preexposure prophylaxis medications for
preventing human immunodeficiency virus.6 Therefore, a newgeneration of intelligent
1 PR N. Otsuka and Proteus® Announce the First U.S. FDA Approval of a Digital Medicine System: ABILIFY
MYCITE® (aripiprazole tablets with sensor). PR Newswire US [serial online]. Nov. 14, 2017: Regional
Business News (accessed Jan. 21, 2020).
2 Id.
3 Christopher Rowland, This $1,650 Pill Will Tell Your Doctors Whether You Have Haken It. Is It the Future of
Medicine? The Washington Post, Apr. 9, 2019, https://www.msn.com/en-ie/news/indepth/this-dolla
r1650-pill-will-tell-your-doctors-whether-youve-taken-it-is-it-the-future-of-medicine/ar-BBWorND?li=
BBPCQrg (accessed Jan. 29, 2020).
4 Anthony RyanHatch,Digital Mental Health Drug Raises Troubling Questions, PhillyVoice.com (June 15, 2018),
https://www.phillyvoice.com/digital-mental-health-drug-cyborg-ethics-abilify-mycite/ (accessed Jan. 21,
2020).
5 Otsuka, AblifyMyCite systemTerms of Use, PrivacyNotice, and Authorization&Consent. Patient authoriza-
tion & consent, https://www.otsuka-us.com/media/static/Abilify-Mycite-Patient-Consent.pdf (accessed
Apr. 30, 2020).
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drugs is arriving and we must properly address the benefits and challenges posed by
them, while preserving our most valuable ethical principles.
Indeed, digital pills might be an excellent tool for monitoring and potentially
improving patients’ adherence to prescriptions, which could result in an impressive
mechanism for avoiding unnecessary healthcare costs and an efficient and excellent
tool for reducing anxiety in patients and their relatives. However, they could also
diminish patient autonomy or reduce their privacy. Keeping this in mind, this article is
aimed at contributing to the adequate use of digital pills by showing the main ethical
issues digital pills involve and proposing measures meant to address them. To this
end, we start by showing the main benefits digital pills might provide to us all, mainly
their potential toward better adherence to treatments. Subsequently, we focus on the
main ethical dilemmas this innovation poses, such as marketing pressures that have
contributed to the emergence of this cutting-edge product, as well as other challenges
facing patient autonomy.
DIGITAL PILLS: THE PEARLS
As mentioned, digital pills might be an extremely useful tool for reliable identification
and minimization of medication non-adherence, a crucial issue in terms of healthcare
systems governance. The lack of adherence to treatment causes huge dysfunctions in
the healthcare sector. In accordance with internationally recognized standards by the
medical profession, a patient is observing a treatment if the average ratio between
medication intake and prescription is ≥80 per cent.7 The World Health Organization
considers that, in the case of chronic diseases, at least 50 per cent of patients show
poor adherence to treatment in global terms,8 a percentage that is even lower in
certain cases.9 In France, for example, a study has shown very low levels of treatment
observation: 36 per cent of heart failure cases, 37 per cent of Type 2 diabetes cases, 40
per cent of hypertension cases, 44per cent of hypercholesterolemia cases, or 53per cent
of osteoporosis cases.10 Thesefigures areparticularlyworrying in the caseof psychiatric
illnesses.11 Non-adherence causes terrible consequences. Indeed, it causes death or
higher complications to a huge number of patients.12 For example, non-adherence is
the largest driver of relapse and hospitalization among patients with disorders such as
schizophrenia, diabetes, and asthma.13
Furthermore, non-adherence leads to considerable yearly cost overruns. In terms of
health from an economic perspective, in the USA, non-optimized medication therapy
7 Grégoire Moutel et al. Le Medicament Connecté, Entre Bienveillance et Surveillance, 34 Analyse des enjeux
éthiques, médecine/sciences 717–22 (2018).
8 Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Report 2003. Geneva: World Health Organi-
sation, n◦ 92 4 154599 2 (2003).
9 Aurel O. Iuga &Maura J. McGuire, Adherence and Health Care Costs, 7 RiskManag Healthc Policy 35, at
4 (2014).
10 Moutel, supra note 7.
11 Palazzo P. Observance Médicamenteuse Et Rechutes Dans La Schizophrénie : Des Neuroleptiques Classiques Aux
APAP, 167 Annal. Médico-Psychol. 308–17 (2009).
12 P. M. Ho, J. S. Rumsfeld, F. A. Masoudi, et al. Effect of Medication Non-adherence on Hospitalization and
Mortality among Patients with Diabetes Mellitus, 166 Arch. Int. Med. 1836–1841 (2006). doi:10.1001/archi
nte.166.17.1836
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costs up to $528.4 billion, which is equivalent to 16 per cent of the total US healthcare
expenditure in 2016.14 For European states, non-adherence is estimated to turn into
an economic loss of e125,000 million each year.15 In terms of medical practice, non-
adherence constitutes a fundamental obstacle to adequate practice of good care, as
‘Whenpatients do not respond to amedication, it can be difficult to determinewhether
the lack of response is due to non-adherence or whether the medication itself is not
effective’.16
To date, physicians cannot really do much to solve the adherence issue. They are
in general entirely dependent on patients’ self-reporting. However, this source is not
reliable. Some patients do not report adequately because they are unable to keep good
records or they are not willing to do so due to reasons such as failure to understand the
instructions, lack of resources, and adverse effects17.
Therefore, the need to improve adherence to treatment is undoubtedly an essential
task for healthcare systems. In recent years, multiple studies have been carried out
with the view to achieving this objective. For example, between 2009 and 12, the
European Commission financed the ABC research project (Ascertaining Barriers for
Compliance: Policies for safe, effective and cost-effective use of medicines in Europe)
within its Seventh Framework Program. This and other studies placed the focus of
better adherence on the need to strengthen the relationship of trust between patient
and doctor, because it is in the direct relationship between the two where it is easiest
to assess the actual observance of treatment. Several additional approaches have been
developed to support adherence, such as the establishment of therapeutic education
groups in healthcare services and patient discussion groups.18
Traditionally, healthcare providers could use directly observed therapy (DOT)
when needed to ensure that patients adhered to the treatment on schedule. Now, new
technologies are turning into a useful tool for physicians to measure adherence with
the same objectivity rates, while overcoming some disadvantages shown by DOTs.
These alternatives include the issuance of follow-up notebooks to be completed by the
patient,which allows thepatient to check their catches andomissions, and thedoctor to
advise the patient during consultations. Alternative tools include electronicmedication
14 Jonathan H. Watanabe, Terry McInnis, Cost of Prescription Drug-Related Morbidity and Mortality, 52 9 Ann.
Pharmacother., 829, at 832 (2018).
15 Unidad de Bioindustrias y Farmacia. Antares Consulting, https://www.antares-consulting.com/es_E
S/main/detallepublicacion/Publicacion/79/apartado/B/idUnidad/1 (accessed Jan. 16, 2020). See:
National Council on Patient Information and Education, Enhancing PrescriptionMedicine
Adherence: A National Action Plan, 7 (2007): Almost half of those polled (49%) said they had
forgotten to take a prescribed medicine; nearly one-third (31%) had not filled a prescription they were given;
nearly three out of 10 (29%) had stopped taking amedicine before the supply ran out; and almost one-quarter
(24%) had taken less than the recommended dosage.
16 C. M. Klugman et al. The Ethics of Smart Pills and Self-acting Devices: Autonomy, Truth-telling , and Trust at the
Dawn of Digital Medicine, 18 Am. J. Bioethics, 38–47 (2018).
17 M. J. Stirratt, J. Dunbar-Jacob, H. M. Crane et al. Self-report Measures of Medication Adherence Behavior:
Recommendations on Optimal Use, 5 Trans. Behav.Med. 470–82 (2015). doi:10.1007/s13142-015-0315-2.
In the case of schizophrenia, see: Peter M. Haddad, Cecilia Brain & Jan Scott, Nonadherence with Antipsychotic
Medication in Schizophrenia: Challenges and Management Strategies. Patient Relat. Outcome Meas. 43, at
48 (2014).
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container lids19 or boxes (called pill boxes, sometimes electronic) containing as many
boxes as there are doses to be taken in a day, which the patient can program to
trigger alerts on their mobile phone.20 Many of these tools raise awareness of new and
precise information provided by the device on a daily basis, and during consultations,
they provide ‘feedback’ with the professional and allow for dialogue.21 Besides, these
medical–device applications not only help patients play an active role in the decision-
making process, but also constitute ameans of supplying the lack of time not dedicated
by the physician,22 as they provide continuous monitoring that allows patients and
physicians immediate access to the patient’s relevant health data.23 Yet, they all rely
on the patient’s will to monitor their adherence to the drug prescribed. Thus, some
scholars have pointed out the need for better alternatives for measuring adherence.24
Are digital pills the response to this query? At first sight, it looks like it. Unlike in the
previous scenario, in a world with digital pills, a cooperative attitude on the part of the
patient is no longer necessary to obtain accurate knowledge of adherence to treatment.
It is enough for patients to agree to use the pills (or for the system to force them to adopt
them) so that their physicians know perfectly what the real adherence to treatment is.
An additional advantage is that this technology could serve to help patients overcome
some of the difficulties they face when trying to follow a treatment, a situation that is
particularly stressful in the case of the elderly or people with mental conditions.
Thus, this wirelessly observed therapy offers better features than the supporting
technologies alreadydescribed,which still rely on thepatient’s capacities andwill (what
if a patient misuses the notebooks or simply does not take the pill even if they remove
it from the box?). Indeed, unlike traditional tools, digital pills register observance
automatically, providing patients with themeans to ensure optimal monitoring of their
drug administration, avoiding missed or duplicated doses.25
Nevertheless, it is important to underscore that reasons behind bad adherence rates
can be diverse andmultiple (not always they consist on a mere distraction to be solved
through a tracking system). When we talk about bad adherence to treatments we are
addressing a complex biosocial phenomenon, as health sciences and social sciences
literature show us. To this regard, if we assume that the operating mode of digital
pills could offer a good solution to solve the adherence issue, we should be aware of
the professional perspective we are adopting—in which no report from the patient is
needed—since fromthenon-adherent patient perspective, the systemcouldbe far from
approaching the true reasons behind bad adherence rates.
19 Klugman, supra note 16.
20 B.B.Granger, S.C. Locke et al. The Digital Drag and Drop Pillbox: Design and Feasibility of a Skill-based Education
Model to Improve Medication Management, 32 J. Cardiovasc. Nurs. E14–20 (2017).
21 Moutel, supra note 7.
22 Dimitra Petrakakia, EvaHilbergb, JustinWaringc,Between Empowerment and Self-discipline: Governing Patients’
Conduct through Technological Self-care, 213 Soc. Sci. Med. 146, at 150 (2018).
23 Ho, infra note 27.
24 S. Garfield, S. et al., Suitability of Measures of Self-reported Medication Adherence for Routine Clinical Use: A
Systematic Review, 11 BMCMed. Res. Methodol. 149 (2011). doi:10.1186/1471-2288-11-149
25 P.R. Chai, Rosen R., Boyer E.W. Ingestible Biosensors for Real-time Medical Adherence Monitoring: myTMed, 16
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To sum up, digital pills provide health systems with precise data on patients’ med-
ication taking26 while informing physicians on whether the failure of a prescribed
treatment is due to the ineffectiveness of the treatment or a significant failure in its
administration. However, this does not necessarily mean that digital pills must be
considered a kind of panacea for adherence issues. Indeed, their use involves relevant
issues that should be balanced against their benefits.
THE PERILS: A COPERNICAN TURN IN THE PATIENT–PHYSICIAN
RELATIONSHIP
First, one needs to understand that the use of digital pills for monitoring patient adher-
ence constitutes a radical turn in the way we focus this issue. Our current healthcare
system is built on a mentality in which trust between clinicians, caregivers, or social
workers and the patient is a fundamental piece.The introductionof digital pills replaces
this framework with a new policy in which monitoring and control play a key role. It is
no longer the patients who reveal data to the physician on a voluntary basis. Instead,
the physician becomes a kind of ‘Big Brother’ who knows everything about the patient
even though they are unwilling to share such information.
Of course, one might reply that this does not necessarily have to happen. Indeed,
this is hardly the case if the patient is willing to use the digital pill. On the other hand,
it is also possible to think that, as the patient will be aware of the knowledge acquired
by the physician, it would be much easier for them to discuss the reasons they are not
observing their treatment, insteadof lying to thehealthcareprovider.Thismight indeed
happen and it is quite difficult to know in advance whether digital pills might cause a
real loss of trust in the physician–patient relationship.
However, the dysfunctions caused by digital pills to the way we approach the
functioning of the healthcare system go beyond the loss (or not) of the notion of trust.
They extend to the possible erosion of the personal relationship between patients and
their physicians. By now, patients usually discuss with their doctor the problems arising
from the follow-up of the prescribed treatment. Nevertheless, in the new scenario,
patients somehowbecome the object of inspection of the health system,whichwatches
closely for any deviation from the correct administration of treatment.
It is very important that patients have sufficient confidence in their doctors to
discuss with them the reasons they are reluctant to take the prescribed medication.
It is also essential that the system provides both with the possibility of building that
relationship through adequate means. Thus, with the use of such smart devices, trust
would be compromised from both the professional and patient perspectives. First, data
generated by the device may cast doubt on the truthfulness of the patient’s self-report.
Conversely, patients may distrust physicians and their therapeutic recommendations
if they receive a different diagnosis from that suggested by the device on which they
rely.27 On the other hand, digital pills open a major gateway to distant and mediated
interaction between doctors and patients, thereby decreasing the need for face-to-
26 J. Frias et al.Effectiveness of Digital Medicines to Improve Clinical Outcomes in Patients with Uncontrolled Hyperten-
sion and Type 2 Diabetes: Prospective, Open-label, Cluster-randomized Pilot Clinical Trial, 19 J. Med. Internet
Res. e246 (2017).
27 Ho, A. & Quick, O. Leaving Patients to Their Own Devices? Smart Technology, Safety and Therapeutic Relation-







niversidad del Pais Vasco user on 26 August 2020
‘Digital pills’ for mental diseases • 7
face communication. Finally, the use of these new technologies may over-technify the
monitoring of treatment or decision-making about a patient. This new scenario, which
constitutes a serious challenge in the health care arena, is by no means inevitable, but
requires the adoption of an appropriate mentality and measures capable of preventing
it. It is essential to keep in mind that technologies should serve to enhance the physi-
cian–patient relationship, rather than to replace it.28. For the sake of maximizing the
usefulness of these cutting-edgemedical technologies in thewaywe conceivemedicine
of even the integral care of patients, wemustmake a proper use of them in terms of both
safety and confidence,29 otherwise, a key aspect of the patient–physician relationship
would be broken: trust. The question, in short, is whether the possible increase in
adherence to treatment would compensate for the decrease in this fundamental value,
confidence, if patients were forced to use to this new technology.30 We sincerely believe
that this is not the case. That is why we advocate a system that is respectful of patient
autonomy and that only allows the use of digital pills in cases in which the patient
encourages it, unless the defense of a public good, such as health or safety, makes it
essential. We will return to this issue later.
PHARMA BENEFITS VERSUS PATIENT INTERESTS:
ETHICAL ISSUES FROM A MARKET PERSPECTIVE
One of the most important ethical dilemmas posed by digital pills comes from the
business model on which they are based. Traditionally, the quality of a pharmaceutical
product depends on its capacity to improve a patient’s health.On this basis, it is possible
to drawup cost–benefit analyses, indexes of limitations of coverage in public healthcare,
or limits on the provision of funds by insurers. In the case of digital pills, the scenario is
much more complicated, as what is offered is not only a medicine, but also a complex
pharmaceutical product that combines both that medicine and a monitoring system
based on cutting-edge technology. Hence, many challenging dilemmas arise. First, it
becomes complicated to compare a systemthat includes adrug thatmaynotbe themost
appropriate for a patient with a drug that may be more efficient in treating the patient’s
specific pathology, but that cannot provide information about adherence. This could
obviously be solved by adapting themonitoring system such that it can be incorporated
into any medicine, but for the moment this scenario is far from reality.
Furthermore, we must not forget that the pharma industry is guided by a strong
interest in enhancing human health, while making a profitable business of it. It may
happen that, for this purpose, it focuses its attention on the monitoring system rather
than on the medicine it incorporates, or worse still, the system is used as a means of
revaluing a medicine that would otherwise be almost obsolete.31
In this respect, the first digital pill approval paves the way for future marketing of
similar drug-device combination products, encouraging other applicants to innovate
similarly over older drugs. It is important to notice that the way that ingestible sensor
canaccompany thedrug is particularly relevant fromthe regulatoryprocessperspective,
28 J. Torous & L. W. Roberts. The Ethical Use of Mobile Health Technology in Clinical Psychiatry, 205 J. Nervous
Mental Dis. 4–8 (2017). doi:10.1097/NMD.0000000000000596
29 Ho, supra note 27.
30 Klugman, supra note 16.
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hence for the entrance into the market. Ingestible sensor physically integrated inside
the drug, as is the case for Abilify MyCite® capsules, requires a New Drug Application
approval—since it falls under the Section 3.2 (e) (1) of Title 21 of the Code of Federal
Regulations, and the aripiprazole is the combination product primary mode of action.
Nevertheless, in case the sensor is not physically integrated in the pill, but embedded
separately inside the same capsule, applicant can take advantage of no requirements
to undergo a new round of regulatory approval. In this way, no FDA approval was
necessary in a recent use of Proteus sensor in a digital oncology pill, within a program
developed with cancer patients in cooperation with University of Minnesota and
Fairview Health Services, since the sensor was ‘loosely packaged’ with the drug in the
capsule.32 Avoiding a time-consuming and costly regulatory process could therefore
constitute a great incentive for applicants to place sooner on the market innovative
products as digital pills.
Innovation in the pharmaceutical sector andbusiness strategies are closely linked, all
the more so since from the beginning of the last decade, the pharmaceutical industry
has been experiencing a phenomenon known as ‘patent cliff’: a massive expiration of
pharmaceutical patents.33 Even Abilify MyCite® developers have mentioned it as a
significant factor for their progress. The pharmaceutical market is based on freemarket
and innovation under the umbrella of solid intellectual property regulation34 . This
translates into a situation where once the patent holder of a blockbuster drug loses the
patent, they automatically lose the market gap occupied by that drug. From then on,
it will be occupied by generic formulations at a lower cost. Against this background,
patent holders deploy various business strategieswith the intentionof patching thehole
in their incomes, or to delay entry ofmost upcoming generic versions into themarket.35
How has this phenomenon affected Otsuka lately? The market for the previous
Abilify formulation—without the ingestible sensor—of thedigital pill version, entailed
a total of $7.5 billion in the USA for the company,36 and operations with this drug in
North America constituted about 40 per cent of Otsuka global sales.37 This put Abilify
ahead in the top-selling drugs in the USA between 2013 and 14,38 the year before the
patent expired in 2015.39 The entry of generic versions into the market after patent
expiry would result in a calamity for the patent holder. And that was the starting point.
In 2015, after several attempts to delay entry of the generics (materialized in various
32 Sara Gerke et al., Ethical and Legal Issues of Ingestible Electronic Sensors, 2 Nat. Electron. 329, at 331 (2019).
33 JackDeRuiter&Pamela L.Holston,Drug Patent Expirations and the “Patent Cliff”, 37 6,U.S. Pharm. 12 (2012).
34 European Commission, Competition DG. Pharmaceutical Sector Inquiry. Final Report. https://ec.europa.eu/
competition/sectors/pharmaceuticals/inquiry/staff_working_paper_part1.pdf (accessed May 5, 2020) and
World Trade Organization, Trade-Related Aspects of Intellectual Property Rights, at 11 https://www.wto.org/e
nglish/docs_e/legal_e/27-trips_01_e.htm (accessedMay 5, 2020).
35 Chie Hoon Song & Jeung-WhanHan, Patent Cliff and Strategic Switch: Exploring Strategic Design Possibilities in
the Pharmaceutical Industry, 5,1 692 SpringerPlus 1, at 3 (2016).
36 Otsuka, Annual Report, at 17, (2014).
37 Id., at 40 (2014), and Leah Ida Harris, The Rise of the Digital Asylum, Mad in America, Sept. 15, 2020, at 15.
38 Id., at 17 (2014).
39 The protection period for the substance patent of ABILIFY will expire in Jan. 2016 in Japan (including the
2-year pediatric exclusivity), in Apr. 2015 in theUSA (including the 6-month pediatric exclusivity) and inOct.
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litigations),40 the first generic-version aripiprazole entered the market. In the face of
this situation, Otsuka, with cooperation from Proteus, introduced an innovation to the
obsolete product—the ingestible sensor—which made it new again, and thus allowed
for ‘evergreen’41 patenting. This strategy enabled themaintenance of their leadership in
the market, at least for the market share represented by patients that did not meet the
proper medication-taking adherence.
The answer to the question of why digital pills have entered the market appears to
be clear: non-adherence tomedication constitutes amajor problem—i.e. especially the
case for antipsychotics.42 Hence a large market share would demand a product that
monitors treatment adherence. But this does not necessarily mean that digital pills
constitute the solution for non-adherence to antipsychotics. Some more reasons are
needed for that.
In this sense, we find some social factors that would support digital pills’ market
entry can be added. The first is a favorable public opinion of treatment compliance by
such patients, as non-compliance could involve a hazard to public safety in case they
behave dangerously toward themselves, their family, or third parties.43 They also have
the potential advantage of reducing possible tensions within the family, or reducing
family anxiety, about treatment non-compliance. Compliance would warrant public—
and private—safety, and digital pills constitute a major step for this purpose, as they
are not subject to the limitations shown by previous electronic reminders in ingestion
tracking.44
The second factor is a favorable attitude from healthcare professionals toward a
treatment that would substitute the monitoring ingestion alternative: the long-acting
injectable antipsychotics (LAIs)—apart from other advantages they might find for
such treatment. LAIs are a means of managing treatment periodically, so taking the
medication does not depend on the patient, hence neither does compliance nor non-
compliance to the patterns given by the physician. AlthoughLAIsmake non-adherence
impossible, they have been observed to have some limitations as well—such as difficul-
ties in finding the proper dose—and are not suitable for all patients.45 In addition, digi-
tal pills overcome the challenges presented by other alternatives posed by professionals
for increasing adherence, such as psychosocial interventions (i.e. psychoeducation),
electronic reminders (i.e. smart pill bottle, SMS), other service interventions (i.e.
access to emergency services, interventions for reducing medicine prices), or financial
40 Id., at 54 (2014); Wolters Kluwer, Drug Makers Given Green Light to Market Generic Versions of Otsuka’s
Abilify Drug, Intellect. Prop. Law Daily, Apr. 17, 2015 and WCG, FDA, FDA News, https://www.fdane
ws.com/articles/183464-otsuka-loses-again-in-challenge-to-fda-green-light-for-competing-drug (accessed
Jan. 16, 2020).
41 Cosgrove et al. define evergreening as ‘a strategy used by industry to effectively extend patent protection by
making small changes to existing products, changes that have almost no added benefit to the patient’, see infra
note 49, at 236.
42 JonathanP. Lacro et al.,Prevalence of and Risk Factors for Medication Nonadherence in Patients with Schizophrenia:
A Comprehensive Review of Recent Literature, 6310 J.Clin.Psychiatry892, at 892 (2002) andLeah IdaHarris,
supra note 37, at 12.
43 Peter M. Haddad, Cecilia Brain & Jan Scott, supra note 17, at 46–47 (2014).








niversidad del Pais Vasco user on 26 August 2020
10 • ‘Digital pills’ for mental diseases
incentives (i.e. payment in return for taking the medicines, although this last option
raises ethical issues).46
Finally, the third key factor relates to a questionable favorable attitude—already
regarded by some as ‘spin’47—in the scientific literature and news reports that some-
how impacts on both attitudes just mentioned: that of the public and the professionals.
There is an underlying concern regarding the scientific support and favorable opinion
presented in several reports, which revolves around the real comparative effectiveness
of this new-generation drug.48 Some authors have already highlighted that the approval
of this first version of digital pills was based on weak clinical trial evidence. Abilify
MyCite is not indicated for adherence, and its impact on it has not been demonstrated.
Cosgrove et al.49 underscore with their systematic review of clinical trials submitted
to the FDA three relevant facts: first, in the reviewed clinical trials, no higher or lower
efficacy is proved in comparisonwith the previous nondigital drug, or with other active
drug comparators (approved in theUSA for the same indication), orwithplacebo,while
at the same timeno clear information about drug safety is provided. Second, the clinical
trials could only prove that the treatment fulfilled the purpose for which it is indicated:
tracking the ingestion; they failed to prove that fact would increase adherence, and
therefore there is no way of knowing for certain if this sort of treatment would improve
patient quality of life, symptoms, or relapses. It only succeeds in demonstrating that the
sensor works properly.50 Third, Cosgrove et al. also point out an emergent scientific
and news tide that distorts interpretation of the evidence shownby clinical trials, which
is manifestly biased by conflicts of interests, presenting a greater impression of the
benefits than that provided by the data.51
Furthermore, it is important to highlight that medicine prices constitute a barrier
to adherence.52 Regarding the data between 1999 and 2015 in the USA about cost-
related prescription non-adherence, a study reported that millions of people do not
46 Peter M. Haddad, Cecilia Brain & Jan Scott, supra note 17, at 55.
47 Cosgrove et al. define spin as ‘a specific way of reporting, intentional or not, to highlight that the beneficial
effect of the experimental treatment, in terms of efficacy or safety, is greater than that shown by the results”, see
infra note 49, at 232.
48 Leah Ida Harris, supra note 37, at 16.
49 Lisa Cosgrove et al., Digital Aripiprazole or Digital Evergreening? A Systematic Review of the Evidence and Its
Dissemination in the Scientific Literature and in the Media, 24 6 BMJ EBM 231 (2019).
50 Daniel J. Lee.Center for Drug Evaluation and Research, Application Number: 207202orig1s000 Clinical review(s),
at 11 https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/207202Orig1s000MedR.pdf (accessed
Jan. 16, 2020).
51 Cosgrove el al. showed that 10 out of 14 papers that reported on the two studies taken into account did not
address the lack of efficacy of the trials. Thirteen out of 14 did not mention the scarcity of data on safety or
the fact that no comparator studies were conducted. In 10 out of 14 papers, authors gave an unsupported
impression of benefit, and in eight out of 14 there was at least one author who had economic links withOtsuka
or Proteus;moreover, in six out of 14 papers, the authors were employees in those companies.When analyzing
news reports, lack of efficacy was not acknowledged in 40 out of 70 cases studied, and 65 out of 70 reports
omitted information about the lack of safety data and did not include any nondigital comparator. In 52 out of
70 cases, benefits not supported by evidence were reported. In 54 out of 70 cases, experts were cited, but in
21 of those 54 cases, those experts had economic ties with the companies mentioned. See Lisa Cosgrove et al.,
supra note 49.
52 Maria Kelly, Suzanne McCarthy & Laura J. Sahm, Knowledge, Attitudes and Beliefs of Patients and Carers
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fill a prescription, postpone a prescription fill, take less medication than prescribed, or
skip doses to save money. These figures increase among working-aged adults, women,
African Americans, the uninsured, people with disabilities, among others.53 This new
pharmaceutical product costs nearly $1700 per month, whereas the generic-version
aripiprazolewithout the sensor costs $20permonth,54 which seems to be relevant inas-
muchas access to treatments is important for patientswith long-termhealth conditions.
Froma fundingprescriptionperspective, it is foreseeable thathealth insurerswill pay for
this innovative treatment according to the provided cost-effectiveness. To this regard,
they would find digital aripiprazole preferable over the nondigital version if its use
translates into reduced costs for the coverage of the patient, hencemaking itworthwhile
to opt for.55 Thus far, there is not enough comparative evidence that shows a major
ability for Abilify MyCite® to improve patient’s health over the nondigital version. As
highlighted above, we can ensure ingestionwill be trackedwith a high precision, but we
cannot anticipate if this circumstance would translate, in all events, in a patient’s health
improvement.
In addition, the very characteristics of the final users of these digital pills (surveil-
lance paranoia and similar) appear to be discouraging for the approval of a pharmaceu-
tical product that takes surveillance to a higher level. In this sense, potential hazards
over the patients derived from the intake of these pills must be approached in a specific
and more in-depth study that has not been performed yet.56 But even in the case that
these ethical barriers are overcome by the benefit an eventual high adherence rate
would generate, then, as already pointed out by some, the lack of effective outcomes
or/and harmful adverse effects that high rates of adherence would generate in patients
on long-term therapies, should be considered.57
All this being said, latest news reveal the short way gone for the once promising
millionaire deal between Proteus and Otsuka. Recently, Proteus has announced that
it will now focus its interests on some other fields such as oncology and infectious
diseases, bringing the agreement withOtsuka to an end. The reason behind its pivoting
direction remains, as pointed by some, in the thorny way chosen by Proteus trying
to first expand its system between patients and healthcare providers in the area of
mental illnesses: not a lot of them seemed comfortable with this new kind of combined
product, a circumstance that turned into too lowsales forOtsuka, and to anunprofitable
and discouraging economic situation for Proteus. Meanwhile, Otsuka would continue
53 Jae Kennedy & Elizabeth Geneva, Medication Costs and Adherence of Treatment Before and After the Affordable
Care Act: 1999-2015, 106 10, AJPH, 2016, 1804-1806, at 1806.
54 Lisa Cosgrove et al., supra note 49, at 236.
55 Klugman, supra note 16, at 42.
56 Lisa Rosenbaum, Swallowing a Spy—The Potential Uses of Digital Adherence Monitoring, 318 2N. Engl. J.Med.
101, 102 (2018) and Lisa Cosgrove et al., supra note 49, at 236.
57 Thomas Insel, Post by Former NIMH Director Thomas Insel: Antipsychotics: Taking the Long View https://www.
nimh.nih.gov/about/directors/thomas-insel/blog/2013/antipsychotics-taking-the-long-view.shtml#1
(accessed Jan. 18, 2020); Lex Wunderink et al., Recovery in Remitted First-Episode Psychosis at 7 Years of
Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy Long-term Follow-up of
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developingmedicines with the use of Proteus system, in a kind of a fully paid-up license
conceded by Proteus for a transitional period.58
We can conclude that this scenario could anticipate the eventual consequences
generated by the entrance in the market of some cutting-edge digital health products.
RESPECT FOR PATIENTS’ AUTONOMY
Patients’ autonomy is a fundamental value. It might be the most important value in
the way we understandmedicine these days. It means that we have finally accepted that
patients have the lastword inmakingdecisions thatwill have consequences in their own
health or life. Therefore, patients’ self-determination constitutes a sort of last boundary
that should never be violated by physicians, healthcare providers, social workers, or
any other person who may be involved in a caring relationship with a patient. This
iron rule cannot be overridden by considerations such as the best interest of the
patient (beneficence).Otherwise, wewould be indulging in paternalism, a practice that
has lasted for too long in healthcare. Do digital pills involve a restriction on patient
autonomy?
The response to this crucial question is not easy to provide, as many different
variables play a role in the answer. Synthetically, wedare say in advance that they neither
violate patient autonomy if this autonomy does not exist, nor violate it without justifi-
cation if there are good reasons to annul it (such as public interest), nor restrict it at all if
patients are competent to consent and show willingness to use the tool, as long as they
provide a real informed consent—which means they have been informed properly—
and freely consent to it. Instead, they would definitively violate such autonomy if the
patientwouldnotprovide real informedconsent, a scenario thatmightbepresentunder
several common circumstances. To this respect we must address very cautiously the
information issue in the user agreements these tracking systems imply, since a lack of
agreement could translate into a lack of access to the treatment, and then into a pressure
over patients to accept some clauses they might not really agree with, thus, making not
an optimally autonomous choice. We will approach this question in Section 6.
Starting from the easiest scenario, we concede that digital pills involve no risk for
autonomy if the patient consents to their use under such circumstances justmentioned:
a really informed consent. This might happen for multiple reasons. For example,
patients with memory loss might be willing to use a system that would serve themwell
to avoid overdoses while reducing the anxiety stemming from the doubt of whether
they have taken the pill. Similarly, patients could be looking forward to benefitting
from a tool that allows them to demonstrate to their doctors that they are following
the provided treatment strictly. Alternatively, they could be proud to use a modern
technology that allows them to incorporate their own impressions about the treatment
in an agile way.
The reasons for acceptance are indeed uncountable, and we do not think that our
mission should be to focus on them. Instead, we should concentrate in cases in which
patients are not willing to adhere to the use of digital pills. In our opinion, this would
58 Dave Muoio, Proteus Parts Ways with Otsuka As It Pivots Toward Oncology, Infectious Disease Treatment Adher-
ence, Mobile Health News, Jan. 14, 2020, and Rebecca Robbins, A Forerunner in ‘Smart Pills’ Adopts a New
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not necessarily act as the definitive reason for avoiding their use. First, one must think
whether acting against the patient’s will violates their autonomy, and then consider
some situations that would yet justify this violation.
The first thing to take into account is the patient’s legal capacity. In case of legally
incapacitated patients, their legal representatives have to decide on whether to adopt
digital pills—respecting the ultimate patient’s interests and counting with their par-
ticipation in the decision-making process as far as possible. This would be the case of
minors or legally incapacitated people.
More complex is the case of other people who do not have a permanent or lasting
restriction on their autonomy, butwhofind themselves in circumstances that advise the
use of digital pills. Imagine, for example, the case of a person affected by a particularly
serious contagious disease that requires the administration of a specific medication for
treatment; or the case of a mental patient whose pathology is associated with violent
outbursts that may endanger other people. In all these cases, the patient poses a threat
to public health. It is therefore necessary to adoptmeasures capable of neutralizing it. At
present, this is done throughmechanisms such as quarantining or confining the patient
in a health facility, where the medication is administered in a forced manner.
The appearance of digital pills promotes an alternative to this situation, as it allows
monitoring the administration of treatment without confining the patient (unless the
dangerof contagion is unavoidable, or patient’s values andpreferences are in accordance
with the confinement, in which cases confinement is legally supported). In these
circumstances, recourse to this new technology would undoubtedly be contrary to
patient autonomy, but much less than the alternative possibility of confinement. This
fact would justify its use even against the patient’s will.
Finally, we must consider the case of the largest group of patients, i.e. those who
possess full faculties for consenting to a treatment andwhose pathologies do not pose a
public health or public safety problem. In all these cases, it is not possible, in our opin-
ion, to justify the use of digital pills if it is not through the consent of the affectedperson.
Moreover, consent must be obtained through a process that provides the patient with
adequate information and guarantees freedom of choice. This is particularly relevant
when we are talking about vulnerable populations, such as the mentally ill, the elderly,
or peoplewith low levels of education, aswell as in peoplewith very little social support.
In these cases, apparent acceptance often hides a desire to not lose the approval of their
scarce social links. As Dotolo et al.59 wrote, ‘When the technology embedded in AMC
is introduced to clients and families by prescribers, its use is normalized, if not tacitly
endorsed. Although formal policymay require informed consent forAMCprescription
use, social workers understand that freely given consent in practice is often complicated
bydifficulty understanding consent forms andprocesses (Schenker, Fernandez, Sudore
& Schillinger, 2011), power asymmetries (Barusch, 1987), and borderline coercive
practices in the context of caregiving (Berridge, 2017). Once the technology is broadly
adopted and normalized, it may be featured in mandated treatment or coercively
encouraged by family members and service providers in the name of beneficence and
safety’.
59 D. Dotolo, Petros, R., & Berridge, C. A Hard Pill to Swallow: Ethical Problems of Digital Medication, 63 Soc.
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In such situations, where using smart devices for healthcare becomes normalized,
not participating in such a self-care technological paradigmcould evenbe contemplated
as a basis for exclusion from access to health services.60 In addition, we may consider
that being aware of the risks a person is exposed to appears to condition the person
into adopting the necessary measures for safeguarding themselves by controlling those
already known risks,61 a scenario in which smart devices could be extremely useful.
Therefore, we need to be particularly vigilant to ensure that patients have good
understanding of the implications of the use of digital tagging. On top of that, we will
have to strive to provide a framework that allows them to express their opinions freely
and support their decisions, attempting to reduce the hostility theymay arouse in their
social support networks, family, or friends.
In any case, the dilemmamust not be seen as an all-or-nothing decision. It is not true
that the alternative to the adoption of digital tagging is the loss of absolute control over
the patient’s behavior. Today, medication management tools that serve these purposes
well even though they limit the patient’s autonomy much less are already in use. It is
true that they probably do not provide with such exact information. However, it will
be necessary to assess in which cases the difference in precision would endorse the
imposition of a measure—the use of digital pills—which represents the considerable
loss of a person’s autonomy.
Finally, it is good to remember that, in general, people are allowed to refuse amedical
treatment due to a number of reasons that are not necessarily rational. It would be
unusual to make an exception in the case of digital pills. It is widely accepted that
choosing between welfare and peace of conscience is a decision to be taken from one’s
owndeepest autonomy, as an expressionof the ownership of rights, without the State or
third parties playing a role in the decision-making—except legal incapacity cases.62 We
could consider the paradigmatic example of a Jehovah’sWitness’s decision in rejecting a
blood transfusion, andhencedeciding topreserve their freedomof consciousness at the
expense of their health or even their life.To support this, we can followStuartMill: ‘The
only part of the conduct of any one, for which he is amenable to society, is that which
concerns others [ . . . ] Over himself, over his own body and mind, the individual is
sovereign’.63 This is the idea that has constituted the guideline in designing a healthcare
system based on autonomy, stripped of paternalism patterns.
AUTONOMY AND USER AGREEMENTS
The use of digital pills implies the need to address a particularly complex issue in terms
of informed consent, which is not present in all physician–patient relationships. As we
have explained, digital pill systems include both a drug and a digital tracking system,
i.e. three electronic devices: the IEM, the patch, and the mobile app. The issue is that
the use of these devices requires the acceptance of some conditions of service, i.e. of a
consent that is unrelated with the consent related to the administration of the drug.
60 Dimitra Petrakakia, Eva Hilbergb & Justin Waringc, supra note 22, at 149.
61 Sonja Erikainen et al., Patienthood and Participation in the Digital era, 5 Digital Health 1, at 6 (2019).
62 Francisco Bueno Arús, El consentimiento del paciente en el tratamiento médico-quirúrgico y la Ley General de
Sanidad, in Estudios de Derecho penal y criminología, 163 (UNED, 1989).
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Here, we may find the first concern about this issue: this privacy policy is sort of a
take-it-or-leave-it contract (usually termed an adherence contract). These agreements
often consist of hundreds of pages written in technical language. Sometimes they
hide clauses that enable manufacturing companies to manage the data collected for
purposes other than monitoring the treatment of the patient involved.64 In these—
mostly common—situations, the patient may be authorizing uses they would not be
able to understand due to the complex terminology. This question keeps the door
open to a wider discussion about data privacy: future data use, eventual collections of
identifiable patient information, access by stakeholders to patient and physician data
collected the mobile app, and the web portal used by them, etc. The second concern
we find is that when the privacy policy is provided only by the mobile app, there is a
risk that document only refers to the app, overlooking sensor and patch privacy issues
about which the user should be informed.
In both situations, the patient would not be making a properly informed decision:
in the first situation, it is because of the lack of understanding about what information
is collected and how it is used; in the second situation, because the patient has no way
of knowing the risks implied. Hence, such privacy policies fail to protect the consumer
that, in this case, meets a patient status whose autonomy is infringed.65
Moreover, such consent is far removed from the norm in the practice ofmedicine, as
it is not based on face-to-face information and a negotiation of the terms of treatment,
but on a user agreement that cannot be discussed with the provider. Pretending that
a person can, by their own means, provide informed and free consent to the use of
these devices is, in these conditions, not very credible. Although some of our current
regulations (such as the General Data Protection Regulation in the European Union
context) accept that a mere ‘box ticking’ serves to capture the existence of consent, the
truth is that this rarely happens.What really happens is that very oftenwe sign a consent
form to access a servicewithouthaving any ideaof the termsof the contract.This,which
is worrying in any sphere of human life, is evenmore so in the field of health. Thismight
become even worse if acceptance of the use agreement becomes a condition of access
to the drug. In such cases, we could think about an absolute perversion of the system of
consent to treatment.
It is therefore necessary to create newmechanisms capable of tackling this problem
effectively, ensuring an effective defense of the patient’s interests. Some authors have
postulated an adaptation of the traditional informed consent.66 This way, healthcare
providers would be the player committed to informing the patient about such privacy
issues. There are some advantages to this proposal: the patient will be informed
before buying the treatment, and will likely better understand when that information
is communicated face-to-face by a trusted person (doctor) instead of from a legal
document. Some would say that studying privacy policies would take a long time for
physicians, apart from exceeding their competences, but, that is, when doctors may
64 Klugman, supra note 16.
65 AmeliaMontgomery, Just What the Doctor Ordered: Protecting Privacy Without Impeding Development of Digital
Pills. 19 1 Vand. J. Ent. & Tech. L. 147, at 168 (2016).
66 Article 29 Data Protection Working Party, Opinion 8/2014 on the on Recent Developments on the Internet of
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ponder the sacrifices they must make and the benefits obtained by prescribing a digital
pill treatment.67
We could certainly think of many other alternatives, which should be carefully
explored in the future. This may well result in a form of paternalism, but in our view, it
would not be an immoral type. Paternalism is only reprehensible when someone tries
to supplant the will of the patient on the basis of the alleged pursuit of his welfare.
However, if the patient is incapable of giving consent because the process makes it
impossible in practice to be adequately informed, then we are faced with a situation
of vulnerability, in which the intervention of a third party to protect their interests is
unavoidable froman ethical point of view.Thus, an administrative intervention capable
of putting conditions on use agreements and their updates, or a system that allows
patients to access reliable information on the real content of these agreements, seems
to be a more than reasonable option.
THE ISSUE OF PRIVACY
The use of digital pills has strong implications on patient privacy. To begin with, it is
necessary to stress that the introductionof this technologyputs an end to themonopoly
of powerover informationon theobservanceof the treatmentpossessedbypatients.Up
until now, and despite the existence of mechanisms that allow adherence to treatment
to bemonitored in some way, the truth is that patients are still the only ones who know
for certain whether they are following the indicated doses. This is due to the simple
fact that, ultimately, only the patients know whether they are taking the prescribed
tablet and when. With the inception of this technology, however, that monopoly was
broken. There is an alternative source for the doctor capable of providing extremely
accurate information. Consequently, the patient’s privacy is unavoidably threatened.
The security of secrecy is no longer in their hands alone.Tobeginwith, their doctorwill
have direct access to the informationwithout having to consult with the patient. This in
itself is not the worst threat to the patient. Healthcare professionals have been used to
professional secrecy for generations and the law protects patients against indiscretion.
Nevertheless, this scenario introduces, in addition, a third party to play a role in
between physician and patient, and who will have access to all the data collected by
the device: the device developer. Developers need that access to procure theminimum
safety and effectiveness levels for the service they are offering. When using that data
properly anonymized and for legally contemplated purposes (such as investigations),
no explicit consent is needed as long as developers comply with the applicable laws.
Butwhenwe talk about highly protected information—health data—this circumstance
raises serious challenges related with data breaches and deanonymization.68 Conse-
quently, while they are accessing the same data as the physician, developers should not
abdicate the same secrecy and confidentiality responsibilities demanded of healthcare
professionals.
Furthermore, we must keep in mind that friends or relatives around patients might
access the data. Different fromhealthcare providers, they are not legally obliged to keep
67 Id., at 173 and 174.
68 GlennCohen et al.,The Legal And Ethical Concerns That Arise From Using Complex Predictive Analytics In Health
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the data confidential, nor have they been trained to do so. On the other hand, it is quite
obvious that the mere knowledge that patients are using this type of device can lead to
great pressure being exerted from their environment to share the data. Take, for exam-
ple, the case of a bipolar person living in the house of a brother, son, or their parents.
Do we not think that there will be many cases in which the relationship of economic
dependence is used to gain access to data? Even more dangerous are the pressures that
insurance companies could exert on their policyholders to gain access to the data. If
it were legally possible, it is likely that some would try to condition the funding of
these devices based on the possibility of appropriating the resulting information, or
at least, offering discounts to policyholders who allow it. Data provided by tracking
devices could be used in health decision-making, either for ensuring compliance with
therapeutic recommendations, or as a consequent fairer distributionof health resources
(‘if you don’t lose weight/don’t take the pills on schedule, then you lose the right to
undergo a surgical procedure/to be covered up to this insurance policy’).69
Finally, we must not underestimate the possibility of the stored data being used
in police/judicial instances, perhaps as a condition for a convict to be released on
bail (‘you take the pills on schedule, or you go back to jail’), or perhaps as evidence
against the patient himself. Some bioethicists consider this method more reliable than
just trusting a detainee/convict’s word.70 This judicial use has already happened in
some cases, for example, ‘in one reported case, police sought a search warrant to access
pacemaker data of a patient they suspected of arson’.71
THE SOCIAL PRESSURE FACTOR
Finally, it is important to bear in mind that the existence of an objective measure of
adherence to treatment can lead to moral, social, or even legal censorship of patients
who sustain in general a lack of adherence to treatment. Lack of adherence to treatment
constitutes, thus, a neglect of responsibilities assumed by the person once they are
aware of their behavior and the risks derived from it. In addition, datafication of
patients provides the possibility of creating new categories of patients according to the
information they generate;72 consequently, we run the risk of constructing a scenario
in which it is possible to distinguish between ‘good’ and ‘bad’ patients depending on
their adherence to treatment. We might even be tempted to impose sanctions on the
second group, a temptation that has already given rise to action in this regard.73 We
could assume that if the individual behavior generates harmover the interests of others,
without the existence of a higher duty that obliges a person to behave that way, they
deservemoral disapproval. Not so if the consequences of that behavior only affect their
own interests.74 The question is whether (or when) this behavior—not taking pills
when prescribed by the physician—constitutes a damage of the interests of others, and
hence could be punished by the community.
69 Sarah Chan, Bioethics in the Big Data Era: Health Care and Beyond, 41 Rev. Bio. y. Der. 3, at 11 (2017).
70 R. Brandom, The Frightening Promise of Self-Tracking Pills, The Verge, Oct. 7, 2015, at 1.
71 Telltale Heart: Pacemaker Data Leads to Arson, Fraud Charges, Fox News U.S. (2017), http://www.foxnews.
com/us/2017/02/08/police-use-data-on-mans-pacemaker-to-chargehim-with-ohio-arson.html
72 Sonja Erikainen et al., supra note 61, at 6.
73 Moutel, supra note 7.
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Inour view, differentiatingbetween ‘good’ and ‘bad’ patients and imposing sanctions
on the latter would be a fatal mistake for many reasons. In general, constructing the
figure of the ‘guilty patient’ is a mistake, a moral injustice that can eventually lead to
State interference in private life. Second, this vision of the world sacralizes science,
thinking that it is possible to objectively set optimal treatment guidelines that everyone
should follow faithfully, although this is not how things work. As we have mentioned,
reasons for non-adherence could be multiple and complex, and we should not fall into
the error of thinking that this phenomenon is only understandable and approachable
in one way. If there is one thing the evidence shows us, it is that each patient responds
individually to a treatment, so unless we are able to optimize the doses for each patient,
we will have to assume amargin of error. Moreover, we have to assume that this margin
empowers the patient to deviate from the intended dosage without there being any
evidence that this will lead to worse treatment performance. Moreover, we must keep
in mind that there are times when strict adherence to treatment can be very difficult or
even harmful for the patient, either because of the physical adverse effects it causes or
because of the lifestyle changes it inevitably imposes.While the healthcare professional
may prioritize healthcare understood to mean perfect adherence to the treatment, the
patient may prioritize well-being in a wider sense, more related with a quality of life
concept.75 Therefore, it seems reasonable to assume that patients would know better
how to deal with a treatment so that their lives are improved effectively instead of the
opposite. This is usually known as ‘self-efficacy’, a concept developed by Bandura,76
which shows the need to pay attention to the circumstances at stake and the wisdom of
the patient’s decision.
FINAL REMARKS
It is quite difficult to deny that smart pills could be useful for increasing adherence to
treatment. If we are able to force patients to consume a medical device that inform
healthcare providers if they have taken the pill, and combine this with the threat of
punishing any lack of adherence with forced confinement of the patient, surely the
intended objective will be achieved. However, this is not, in our view, the ideal way of
ensuring better adherence. If studies show anything, it is that adherence improves with
better understanding of the need for medication and a fluid and permanent dialogue
between the patient and healthcare workers, whichmakes it possible to reduce harmful
adverse effects. Obviously, there will be patients for whom all this is impossible. There
will also be others where resistance to treatment is irrational. But, in general, we believe
that these new systems should ideally be seen as a means of complementing traditional
strategies for promoting adherence to treatment, and not as a substitute. Only in this
manner can we obtain a final result that is not reduced to an increase in adherence
rates subject to inadequate limitation of patient autonomy. As stated, ‘Automatic and
computerized data collection, related to the follow-up of a treatment, will require us
to consider the following the question of benefit/risk assessment. The evaluation of
75 Victoria Camps, Una vida de calidad. Reflexiones sobre bioética, at 72 and 73 (2001) and Rosana
Triviño, El peso de la conciencia. La objeción en el ejercicio de las profesiones sanitarias
(2014).
76 Bandura A. Health Functioning, in SELF-EFFICACY: THE EXERCISE OF CONTROL, 259–318 (SF
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a connected device will require to study how its use improves or not the quality of
the follow-up and, ultimately, the patient’s quality of life. And to analyze if risks would
not offset these potential benefits (whether or not fundamental freedoms are infringed,
psychological impact of fear of surveillance, increased anxiety, etc.)’.77
FUNDING
Iñigo de Miguel Beriain’s work received funding from the EU Commission, H2020
SWAFS Programme, PANELFIT Project, research grant number 788039. Marina
Morla’s work received funding from the Programa Propio de Investigación de la
Universidad de León.







niversidad del Pais Vasco user on 26 August 2020












This project has received funding from 
the European Union’s Horizon 2020 
research and innovation programme 







Iñigo de Miguel Beriain, Marina Morla González, 
‘Digital pills’ for mental diseases: an ethical and 
social analysis of the issues behind the concept, 
Journal of Law and the Biosciences, lsaa040, 
https://doi.org/10.1093/jlb/lsaa040 
 
